FDA Inspection 1263112 — Shilpa Pharma Lifesciences Limited
The FDA completed an inspection of Shilpa Pharma Lifesciences Limited on March 7, 2025 in Deosugur. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- March 7, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Deosugur (India)